Using a blood DNA test to guide treatment for diffuse large B-cell lymphoma
Tests a blood DNA test to guide treatment in adults with lymphoma.
Plain-language title generated from the registry record
Registry title: Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
Key facts
- Where
- Suzhou, ChinaSee the site
Where in China
- The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Soochow University
- Trial code
- NCT06289959
- Record updated
- 4 March 2024
- Original description
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.Read full original descriptionShow less
A Prospective, Single-Center, Randomized, Controlled Study Guiding the Treatment of Diffuse Large B-Cell Lymphoma Patients Based on Plasma cfDNA Testing
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.
Inclusion: Age ≥ 18 years, gender not specified; Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathological examination. Patients should test positive for plasma cfDNA before treatment (defined as positive for point mutations, CNV, IgH-related fusion, or IG clonal rearrangement) and achieve complete metabolic remission after 6 cycles of R-CHOP chemotherapy (evaluated by Lugano response assessment criteria); Patients for whom the researcher predicts a life expectancy of >6 months; Signed informed consent form.
Exclusion: Patients who have undergone autologous stem cell transplantation; Other concurrent and uncontrolled diseases that researchers believe may affect the medical condition of patients participating in the study; Patients with a history of other malignant tumors, except for basal cell carcinoma of the skin or in situ cervical cancer; Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, and other such conditions; Patients with mental illness or others known or suspected to be unable to fully comply with the study protocol; HbsAg-positive patients who need to undergo HBV-DNA testing and can only be included if they seroconvert. Additionally, if the HbsAg test is negative but the HBcAb test is positive (regardless of HbsAb status), HBV-DNA testing is also required. If the result is positive, inclusion is possible only after seroconversion; HIV-infected individuals; Primary central nervous system lymphoma; Pregnant or lactating women.